Cargando…
Computational Drug Target Screening through Protein Interaction Profiles
The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Targ...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109486/ https://www.ncbi.nlm.nih.gov/pubmed/27845365 http://dx.doi.org/10.1038/srep36969 |
_version_ | 1782467550580310016 |
---|---|
author | Vilar, Santiago Quezada, Elías Uriarte, Eugenio Costanzi, Stefano Borges, Fernanda Viña, Dolores Hripcsak, George |
author_facet | Vilar, Santiago Quezada, Elías Uriarte, Eugenio Costanzi, Stefano Borges, Fernanda Viña, Dolores Hripcsak, George |
author_sort | Vilar, Santiago |
collection | PubMed |
description | The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC(50) values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC(50) in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin-3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety. |
format | Online Article Text |
id | pubmed-5109486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-51094862016-11-25 Computational Drug Target Screening through Protein Interaction Profiles Vilar, Santiago Quezada, Elías Uriarte, Eugenio Costanzi, Stefano Borges, Fernanda Viña, Dolores Hripcsak, George Sci Rep Article The development of computational methods to discover novel drug-target interactions on a large scale is of great interest. We propose a new method for virtual screening based on protein interaction profile similarity to discover new targets for molecules, including existing drugs. We calculated Target Interaction Profile Fingerprints (TIPFs) based on ChEMBL database to evaluate drug similarity and generated new putative compound-target candidates from the non-intersecting targets in each pair of compounds. A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1) enzyme through molecular docking and experimental assays. The drug ethoxzolamide and the natural compound piperlongumine, present in Piper longum L, showed hMAO-B activity with IC(50) values of 25 and 65 μM respectively. Five candidates, including lapatinib, SB-202190, RO-316233, GW786460X and indirubin-3′-monoxime were tested against human COX-1. Compounds SB-202190 and RO-316233 showed a IC(50) in hCOX-1 of 24 and 25 μM respectively (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental conditions). Lapatinib and indirubin-3′-monoxime showed moderate hCOX-1 activity (19.5% and 28% of enzyme inhibition at 25 μM respectively). Our modeling constitutes a multi-target predictor for large scale virtual screening with potential in lead discovery, repositioning and drug safety. Nature Publishing Group 2016-11-15 /pmc/articles/PMC5109486/ /pubmed/27845365 http://dx.doi.org/10.1038/srep36969 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Vilar, Santiago Quezada, Elías Uriarte, Eugenio Costanzi, Stefano Borges, Fernanda Viña, Dolores Hripcsak, George Computational Drug Target Screening through Protein Interaction Profiles |
title | Computational Drug Target Screening through Protein Interaction Profiles |
title_full | Computational Drug Target Screening through Protein Interaction Profiles |
title_fullStr | Computational Drug Target Screening through Protein Interaction Profiles |
title_full_unstemmed | Computational Drug Target Screening through Protein Interaction Profiles |
title_short | Computational Drug Target Screening through Protein Interaction Profiles |
title_sort | computational drug target screening through protein interaction profiles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109486/ https://www.ncbi.nlm.nih.gov/pubmed/27845365 http://dx.doi.org/10.1038/srep36969 |
work_keys_str_mv | AT vilarsantiago computationaldrugtargetscreeningthroughproteininteractionprofiles AT quezadaelias computationaldrugtargetscreeningthroughproteininteractionprofiles AT uriarteeugenio computationaldrugtargetscreeningthroughproteininteractionprofiles AT costanzistefano computationaldrugtargetscreeningthroughproteininteractionprofiles AT borgesfernanda computationaldrugtargetscreeningthroughproteininteractionprofiles AT vinadolores computationaldrugtargetscreeningthroughproteininteractionprofiles AT hripcsakgeorge computationaldrugtargetscreeningthroughproteininteractionprofiles |